Literature DB >> 19590949

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.

Konstantinos P Economopoulos1, Theodoros N Sergentanis.   

Abstract

MDM2 SNP309 is a single nucleotide T > G polymorphism present in intron 1 of the MDM2 gene. A variety of case-control studies have been published evaluating the association between MDM2 SNP309 and breast cancer risk. However, the published studies, as well as the subsequent meta-analyses, have yielded contradictory results. This meta-analysis aims to examine whether MDM SNP309 polymorphism may exert a differential effect on breast cancer risk along with race. Eligible articles were identified by a search of MEDLINE, Cochrane and EMBASE bibliographical databases for the period July 1993 to June 2009; 16 case-control studies were eligible (12,986 breast cancer cases, 12,993 controls). Subanalyses in case-control studies conducted on Chinese (3 studies, 892 cases, 1,435 controls) and non-Chinese populations (13 studies, 12,094 cases, 11,558 controls) were performed. All pooled odds ratios (ORs) were derived from fixed-effects models given that the between-study heterogeneity was not statistically significant. Subanalysis on Chinese subjects demonstrated that GT and GG genotype were associated with increased breast cancer risk (pooled OR = 1.272, 95% CI 1.025-1.578 and pooled OR = 1.323, 95% CI 1.034-1.694, respectively); as a result the overall effect of the G allele was statistically significant (pooled OR = 1.287, 95% CI 1.048-1.579). On the contrary, no significant associations between MDM2 SNP309 status and breast cancer risk were demonstrated in non-Chinese populations. In conclusion, the association between MDM2 SNP309 and breast cancer is modified by race. MDM2 SNP309 represents a risk factor for breast cancer in Chinese women but not in non-Chinese women. This phenomenon is analogous to that described in the context of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590949     DOI: 10.1007/s10549-009-0467-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  38 in total

Review 1.  Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Transcription       Date:  2011 Sep-Oct

2.  Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Authors:  Hongtao Cheng; Biao Ma; Ran Jiang; Wei Wang; Hui Guo; Na Shen; Dapeng Li; Qunzi Zhao; Rui Wang; Pengfei Yi; Yue Zhao; Zeming Liu; Tao Huang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

3.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

4.  MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.

Authors:  Fang Fang; Xiao-Jia Yu; Lu Yu; Lei Yao
Journal:  Med Oncol       Date:  2010-05-26       Impact factor: 3.064

5.  Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.

Authors:  Woon-Puay Koh; David Van Den Berg; Aizhen Jin; Renwei Wang; Jian-Min Yuan; Mimi C Yu
Journal:  Breast Cancer Res Treat       Date:  2011-07-21       Impact factor: 4.872

6.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

Review 7.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

8.  The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.

Authors:  Jie Yang; Wen Gao; Ning-Hong Song; Wei Wang; Jie-Xiu Zhang; Pei Lu; Li-Xin Hua; Min Gu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

9.  HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study.

Authors:  Flora Zagouri; Theodoros N Sergentanis; Maria Gazouli; Alexandra Tsigginou; Constantine Dimitrakakis; Irene Papaspyrou; Evaggelos Eleutherakis-Papaiakovou; Dimosthenis Chrysikos; George Theodoropoulos; George C Zografos; Aris Antsaklis; Athanassios-Meletios Dimopoulos; Christos A Papadimitriou
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

10.  HTERT MNS16A polymorphism in breast cancer: a case-control study.

Authors:  Flora Zagouri; Theodoros N Sergentanis; Maria Gazouli; Alexandra Tsigginou; Constantine Dimitrakakis; Evaggelos Eleutherakis-Papaiakovou; Irene Papaspyrou; Dimosthenis Chrysikos; George Theodoropoulos; George C Zografos; Aris Antsaklis; Athanassios-Meletios Dimopoulos; Christos A Papadimitriou
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.